Payment overview · 2025
General Payments
$257.62
8 reported records · 6 companies
Healthcare provider profile · identity verified
Joseph Kim, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · RANDOLPH, NJ · NPI 1689640625
Verified facts
What the public records show
CMS Open Payments records show Joseph Kim, M.D. received $257.62 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 46.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fetroja.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
Shionogi Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fetroja as an associated drug or biological on 4885 records involving 1879 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fetroja by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $119.03 | 46.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $67.44 | 26.2% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $19.75 | 7.7% | 1 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $18.36 | 7.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.97 | 7.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.07 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $257.62 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $119.03 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $44.39 | 2 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| PREVYMIS Normalized: prevymis |
Drug | Merck Sharp & Dohme LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Fetroja fetroja |
2025 | Fetroja | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Shionogi Inc Exact reporting entity; no affiliate inference |
2025 | Fetroja open payments reported associated product |
CMS Open Payments — General Payments 4885 supporting records · 1879 recipient NPIs · example record 1250711130 |
Fetroja · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Warfarin Sodium | Warfarin Sodium | 243 | suppressed |
| Baclofen | Baclofen | 154 | 12 |
| Gabapentin | Gabapentin | 91 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 79 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 22 |
| Ceftriaxone | Ceftriaxone Sodium | 65 | 14 |
| Gentamicin Sulfate | Gentamicin Sulfate | 60 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 57 | 14 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 54 | 16 |
| Mirtazapine | Mirtazapine | 53 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 20 |
| Cefuroxime | Cefuroxime Axetil | 48 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Eliquis | Apixaban | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 34 | suppressed |
| Cefadroxil | Cefadroxil | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Procrit | Epoetin Alfa | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Amoxicillin | Amoxicillin | 27 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 11 |
| Ertapenem | Ertapenem Sodium | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 22 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Penicillin G Potassium | Penicillin G Potassium | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Isoniazid | Isoniazid | 15 | suppressed |
| Fetroja | Cefiderocol Sulfate Tosylate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Tyrvaya | Varenicline Tartrate | 14 | suppressed |
| Daptomycin | Daptomycin | 13 | suppressed |
| Minocin | Minocycline Hcl | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $257.62 · 8 records | ABBVIE INC. | Arikayce, CUTAQUIG, DALVANCE, Fetroja, NUZYRA, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, PIFELTRO, PREVYMIS, ZERBAXA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fetroja play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error